IT
Iambic Therapeutics, Inc.
SEC filingBiotechnology · San Diego, CA
Amount raised$66Msold at filing
Total offering$66.5M$535K still open
Investors in the raise16count reported to the SEC
FiledSep 9, 2026first sale Aug 14, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Pete OlsonExecutive Officer
Shalini SharpDirector
Fred ManbyExecutive Officer, Director
Evan RachlinDirector
Michael SecoraExecutive Officer
William RastetterDirector
Neil JosephsonExecutive Officer
Thomas MillerExecutive Officer, Director
Jishnu BhattacharjeeDirector
Mary TagliaferriDirector
Kurt von EmsterDirector
R. Jacob VogelsteinDirector
Executive officers, directors and promoters as listed on the Form D.